-
BraTS-PEDs: Results of the Multi-Consortium International Pediatric Brain Tumor Segmentation Challenge 2023
Authors:
Anahita Fathi Kazerooni,
Nastaran Khalili,
Xinyang Liu,
Debanjan Haldar,
Zhifan Jiang,
Anna Zapaishchykova,
Julija Pavaine,
Lubdha M. Shah,
Blaise V. Jones,
Nakul Sheth,
Sanjay P. Prabhu,
Aaron S. McAllister,
Wenxin Tu,
Khanak K. Nandolia,
Andres F. Rodriguez,
Ibraheem Salman Shaikh,
Mariana Sanchez Montano,
Hollie Anne Lai,
Maruf Adewole,
Jake Albrecht,
Udunna Anazodo,
Hannah Anderson,
Syed Muhammed Anwar,
Alejandro Aristizabal,
Sina Bagheri
, et al. (55 additional authors not shown)
Abstract:
Pediatric central nervous system tumors are the leading cause of cancer-related deaths in children. The five-year survival rate for high-grade glioma in children is less than 20%. The development of new treatments is dependent upon multi-institutional collaborative clinical trials requiring reproducible and accurate centralized response assessment. We present the results of the BraTS-PEDs 2023 cha…
▽ More
Pediatric central nervous system tumors are the leading cause of cancer-related deaths in children. The five-year survival rate for high-grade glioma in children is less than 20%. The development of new treatments is dependent upon multi-institutional collaborative clinical trials requiring reproducible and accurate centralized response assessment. We present the results of the BraTS-PEDs 2023 challenge, the first Brain Tumor Segmentation (BraTS) challenge focused on pediatric brain tumors. This challenge utilized data acquired from multiple international consortia dedicated to pediatric neuro-oncology and clinical trials. BraTS-PEDs 2023 aimed to evaluate volumetric segmentation algorithms for pediatric brain gliomas from magnetic resonance imaging using standardized quantitative performance evaluation metrics employed across the BraTS 2023 challenges. The top-performing AI approaches for pediatric tumor analysis included ensembles of nnU-Net and Swin UNETR, Auto3DSeg, or nnU-Net with a self-supervised framework. The BraTSPEDs 2023 challenge fostered collaboration between clinicians (neuro-oncologists, neuroradiologists) and AI/imaging scientists, promoting faster data sharing and the development of automated volumetric analysis techniques. These advancements could significantly benefit clinical trials and improve the care of children with brain tumors.
△ Less
Submitted 16 July, 2024; v1 submitted 11 July, 2024;
originally announced July 2024.
-
The RSNA Abdominal Traumatic Injury CT (RATIC) Dataset
Authors:
Jeffrey D. Rudie,
Hui-Ming Lin,
Robyn L. Ball,
Sabeena Jalal,
Luciano M. Prevedello,
Savvas Nicolaou,
Brett S. Marinelli,
Adam E. Flanders,
Kirti Magudia,
George Shih,
Melissa A. Davis,
John Mongan,
Peter D. Chang,
Ferco H. Berger,
Sebastiaan Hermans,
Meng Law,
Tyler Richards,
Jan-Peter Grunz,
Andreas Steven Kunz,
Shobhit Mathur,
Sandro Galea-Soler,
Andrew D. Chung,
Saif Afat,
Chin-Chi Kuo,
Layal Aweidah
, et al. (15 additional authors not shown)
Abstract:
The RSNA Abdominal Traumatic Injury CT (RATIC) dataset is the largest publicly available collection of adult abdominal CT studies annotated for traumatic injuries. This dataset includes 4,274 studies from 23 institutions across 14 countries. The dataset is freely available for non-commercial use via Kaggle at https://www.kaggle.com/competitions/rsna-2023-abdominal-trauma-detection. Created for the…
▽ More
The RSNA Abdominal Traumatic Injury CT (RATIC) dataset is the largest publicly available collection of adult abdominal CT studies annotated for traumatic injuries. This dataset includes 4,274 studies from 23 institutions across 14 countries. The dataset is freely available for non-commercial use via Kaggle at https://www.kaggle.com/competitions/rsna-2023-abdominal-trauma-detection. Created for the RSNA 2023 Abdominal Trauma Detection competition, the dataset encourages the development of advanced machine learning models for detecting abdominal injuries on CT scans. The dataset encompasses detection and classification of traumatic injuries across multiple organs, including the liver, spleen, kidneys, bowel, and mesentery. Annotations were created by expert radiologists from the American Society of Emergency Radiology (ASER) and Society of Abdominal Radiology (SAR). The dataset is annotated at multiple levels, including the presence of injuries in three solid organs with injury grading, image-level annotations for active extravasations and bowel injury, and voxelwise segmentations of each of the potentially injured organs. With the release of this dataset, we hope to facilitate research and development in machine learning and abdominal trauma that can lead to improved patient care and outcomes.
△ Less
Submitted 29 May, 2024;
originally announced May 2024.
-
Brain Tumor Segmentation (BraTS) Challenge 2024: Meningioma Radiotherapy Planning Automated Segmentation
Authors:
Dominic LaBella,
Katherine Schumacher,
Michael Mix,
Kevin Leu,
Shan McBurney-Lin,
Pierre Nedelec,
Javier Villanueva-Meyer,
Jonathan Shapey,
Tom Vercauteren,
Kazumi Chia,
Omar Al-Salihi,
Justin Leu,
Lia Halasz,
Yury Velichko,
Chunhao Wang,
John Kirkpatrick,
Scott Floyd,
Zachary J. Reitman,
Trey Mullikin,
Ulas Bagci,
Sean Sachdev,
Jona A. Hattangadi-Gluth,
Tyler Seibert,
Nikdokht Farid,
Connor Puett
, et al. (45 additional authors not shown)
Abstract:
The 2024 Brain Tumor Segmentation Meningioma Radiotherapy (BraTS-MEN-RT) challenge aims to advance automated segmentation algorithms using the largest known multi-institutional dataset of radiotherapy planning brain MRIs with expert-annotated target labels for patients with intact or postoperative meningioma that underwent either conventional external beam radiotherapy or stereotactic radiosurgery…
▽ More
The 2024 Brain Tumor Segmentation Meningioma Radiotherapy (BraTS-MEN-RT) challenge aims to advance automated segmentation algorithms using the largest known multi-institutional dataset of radiotherapy planning brain MRIs with expert-annotated target labels for patients with intact or postoperative meningioma that underwent either conventional external beam radiotherapy or stereotactic radiosurgery. Each case includes a defaced 3D post-contrast T1-weighted radiotherapy planning MRI in its native acquisition space, accompanied by a single-label "target volume" representing the gross tumor volume (GTV) and any at-risk postoperative site. Target volume annotations adhere to established radiotherapy planning protocols, ensuring consistency across cases and institutions. For preoperative meningiomas, the target volume encompasses the entire GTV and associated nodular dural tail, while for postoperative cases, it includes at-risk resection cavity margins as determined by the treating institution. Case annotations were reviewed and approved by expert neuroradiologists and radiation oncologists. Participating teams will develop, containerize, and evaluate automated segmentation models using this comprehensive dataset. Model performance will be assessed using an adapted lesion-wise Dice Similarity Coefficient and the 95% Hausdorff distance. The top-performing teams will be recognized at the Medical Image Computing and Computer Assisted Intervention Conference in October 2024. BraTS-MEN-RT is expected to significantly advance automated radiotherapy planning by enabling precise tumor segmentation and facilitating tailored treatment, ultimately improving patient outcomes.
△ Less
Submitted 15 August, 2024; v1 submitted 28 May, 2024;
originally announced May 2024.
-
The 2024 Brain Tumor Segmentation (BraTS) Challenge: Glioma Segmentation on Post-treatment MRI
Authors:
Maria Correia de Verdier,
Rachit Saluja,
Louis Gagnon,
Dominic LaBella,
Ujjwall Baid,
Nourel Hoda Tahon,
Martha Foltyn-Dumitru,
Jikai Zhang,
Maram Alafif,
Saif Baig,
Ken Chang,
Gennaro D'Anna,
Lisa Deptula,
Diviya Gupta,
Muhammad Ammar Haider,
Ali Hussain,
Michael Iv,
Marinos Kontzialis,
Paul Manning,
Farzan Moodi,
Teresa Nunes,
Aaron Simon,
Nico Sollmann,
David Vu,
Maruf Adewole
, et al. (60 additional authors not shown)
Abstract:
Gliomas are the most common malignant primary brain tumors in adults and one of the deadliest types of cancer. There are many challenges in treatment and monitoring due to the genetic diversity and high intrinsic heterogeneity in appearance, shape, histology, and treatment response. Treatments include surgery, radiation, and systemic therapies, with magnetic resonance imaging (MRI) playing a key r…
▽ More
Gliomas are the most common malignant primary brain tumors in adults and one of the deadliest types of cancer. There are many challenges in treatment and monitoring due to the genetic diversity and high intrinsic heterogeneity in appearance, shape, histology, and treatment response. Treatments include surgery, radiation, and systemic therapies, with magnetic resonance imaging (MRI) playing a key role in treatment planning and post-treatment longitudinal assessment. The 2024 Brain Tumor Segmentation (BraTS) challenge on post-treatment glioma MRI will provide a community standard and benchmark for state-of-the-art automated segmentation models based on the largest expert-annotated post-treatment glioma MRI dataset. Challenge competitors will develop automated segmentation models to predict four distinct tumor sub-regions consisting of enhancing tissue (ET), surrounding non-enhancing T2/fluid-attenuated inversion recovery (FLAIR) hyperintensity (SNFH), non-enhancing tumor core (NETC), and resection cavity (RC). Models will be evaluated on separate validation and test datasets using standardized performance metrics utilized across the BraTS 2024 cluster of challenges, including lesion-wise Dice Similarity Coefficient and Hausdorff Distance. Models developed during this challenge will advance the field of automated MRI segmentation and contribute to their integration into clinical practice, ultimately enhancing patient care.
△ Less
Submitted 28 May, 2024;
originally announced May 2024.
-
Analysis of the BraTS 2023 Intracranial Meningioma Segmentation Challenge
Authors:
Dominic LaBella,
Ujjwal Baid,
Omaditya Khanna,
Shan McBurney-Lin,
Ryan McLean,
Pierre Nedelec,
Arif Rashid,
Nourel Hoda Tahon,
Talissa Altes,
Radhika Bhalerao,
Yaseen Dhemesh,
Devon Godfrey,
Fathi Hilal,
Scott Floyd,
Anastasia Janas,
Anahita Fathi Kazerooni,
John Kirkpatrick,
Collin Kent,
Florian Kofler,
Kevin Leu,
Nazanin Maleki,
Bjoern Menze,
Maxence Pajot,
Zachary J. Reitman,
Jeffrey D. Rudie
, et al. (96 additional authors not shown)
Abstract:
We describe the design and results from the BraTS 2023 Intracranial Meningioma Segmentation Challenge. The BraTS Meningioma Challenge differed from prior BraTS Glioma challenges in that it focused on meningiomas, which are typically benign extra-axial tumors with diverse radiologic and anatomical presentation and a propensity for multiplicity. Nine participating teams each developed deep-learning…
▽ More
We describe the design and results from the BraTS 2023 Intracranial Meningioma Segmentation Challenge. The BraTS Meningioma Challenge differed from prior BraTS Glioma challenges in that it focused on meningiomas, which are typically benign extra-axial tumors with diverse radiologic and anatomical presentation and a propensity for multiplicity. Nine participating teams each developed deep-learning automated segmentation models using image data from the largest multi-institutional systematically expert annotated multilabel multi-sequence meningioma MRI dataset to date, which included 1000 training set cases, 141 validation set cases, and 283 hidden test set cases. Each case included T2, T2/FLAIR, T1, and T1Gd brain MRI sequences with associated tumor compartment labels delineating enhancing tumor, non-enhancing tumor, and surrounding non-enhancing T2/FLAIR hyperintensity. Participant automated segmentation models were evaluated and ranked based on a scoring system evaluating lesion-wise metrics including dice similarity coefficient (DSC) and 95% Hausdorff Distance. The top ranked team had a lesion-wise median dice similarity coefficient (DSC) of 0.976, 0.976, and 0.964 for enhancing tumor, tumor core, and whole tumor, respectively and a corresponding average DSC of 0.899, 0.904, and 0.871, respectively. These results serve as state-of-the-art benchmarks for future pre-operative meningioma automated segmentation algorithms. Additionally, we found that 1286 of 1424 cases (90.3%) had at least 1 compartment voxel abutting the edge of the skull-stripped image edge, which requires further investigation into optimal pre-processing face anonymization steps.
△ Less
Submitted 15 May, 2024;
originally announced May 2024.
-
The Brain Tumor Segmentation in Pediatrics (BraTS-PEDs) Challenge: Focus on Pediatrics (CBTN-CONNECT-DIPGR-ASNR-MICCAI BraTS-PEDs)
Authors:
Anahita Fathi Kazerooni,
Nastaran Khalili,
Xinyang Liu,
Deep Gandhi,
Zhifan Jiang,
Syed Muhammed Anwar,
Jake Albrecht,
Maruf Adewole,
Udunna Anazodo,
Hannah Anderson,
Ujjwal Baid,
Timothy Bergquist,
Austin J. Borja,
Evan Calabrese,
Verena Chung,
Gian-Marco Conte,
Farouk Dako,
James Eddy,
Ivan Ezhov,
Ariana Familiar,
Keyvan Farahani,
Andrea Franson,
Anurag Gottipati,
Shuvanjan Haldar,
Juan Eugenio Iglesias
, et al. (46 additional authors not shown)
Abstract:
Pediatric tumors of the central nervous system are the most common cause of cancer-related death in children. The five-year survival rate for high-grade gliomas in children is less than 20%. Due to their rarity, the diagnosis of these entities is often delayed, their treatment is mainly based on historic treatment concepts, and clinical trials require multi-institutional collaborations. Here we pr…
▽ More
Pediatric tumors of the central nervous system are the most common cause of cancer-related death in children. The five-year survival rate for high-grade gliomas in children is less than 20%. Due to their rarity, the diagnosis of these entities is often delayed, their treatment is mainly based on historic treatment concepts, and clinical trials require multi-institutional collaborations. Here we present the CBTN-CONNECT-DIPGR-ASNR-MICCAI BraTS-PEDs challenge, focused on pediatric brain tumors with data acquired across multiple international consortia dedicated to pediatric neuro-oncology and clinical trials. The CBTN-CONNECT-DIPGR-ASNR-MICCAI BraTS-PEDs challenge brings together clinicians and AI/imaging scientists to lead to faster development of automated segmentation techniques that could benefit clinical trials, and ultimately the care of children with brain tumors.
△ Less
Submitted 11 July, 2024; v1 submitted 23 April, 2024;
originally announced April 2024.
-
The Brain Tumor Segmentation (BraTS-METS) Challenge 2023: Brain Metastasis Segmentation on Pre-treatment MRI
Authors:
Ahmed W. Moawad,
Anastasia Janas,
Ujjwal Baid,
Divya Ramakrishnan,
Rachit Saluja,
Nader Ashraf,
Leon Jekel,
Raisa Amiruddin,
Maruf Adewole,
Jake Albrecht,
Udunna Anazodo,
Sanjay Aneja,
Syed Muhammad Anwar,
Timothy Bergquist,
Evan Calabrese,
Veronica Chiang,
Verena Chung,
Gian Marco Marco Conte,
Farouk Dako,
James Eddy,
Ivan Ezhov,
Ariana Familiar,
Keyvan Farahani,
Juan Eugenio Iglesias,
Zhifan Jiang
, et al. (206 additional authors not shown)
Abstract:
The translation of AI-generated brain metastases (BM) segmentation into clinical practice relies heavily on diverse, high-quality annotated medical imaging datasets. The BraTS-METS 2023 challenge has gained momentum for testing and benchmarking algorithms using rigorously annotated internationally compiled real-world datasets. This study presents the results of the segmentation challenge and chara…
▽ More
The translation of AI-generated brain metastases (BM) segmentation into clinical practice relies heavily on diverse, high-quality annotated medical imaging datasets. The BraTS-METS 2023 challenge has gained momentum for testing and benchmarking algorithms using rigorously annotated internationally compiled real-world datasets. This study presents the results of the segmentation challenge and characterizes the challenging cases that impacted the performance of the winning algorithms. Untreated brain metastases on standard anatomic MRI sequences (T1, T2, FLAIR, T1PG) from eight contributed international datasets were annotated in stepwise method: published UNET algorithms, student, neuroradiologist, final approver neuroradiologist. Segmentations were ranked based on lesion-wise Dice and Hausdorff distance (HD95) scores. False positives (FP) and false negatives (FN) were rigorously penalized, receiving a score of 0 for Dice and a fixed penalty of 374 for HD95. Eight datasets comprising 1303 studies were annotated, with 402 studies (3076 lesions) released on Synapse as publicly available datasets to challenge competitors. Additionally, 31 studies (139 lesions) were held out for validation, and 59 studies (218 lesions) were used for testing. Segmentation accuracy was measured as rank across subjects, with the winning team achieving a LesionWise mean score of 7.9. Common errors among the leading teams included false negatives for small lesions and misregistration of masks in space.The BraTS-METS 2023 challenge successfully curated well-annotated, diverse datasets and identified common errors, facilitating the translation of BM segmentation across varied clinical environments and providing personalized volumetric reports to patients undergoing BM treatment.
△ Less
Submitted 17 June, 2024; v1 submitted 1 June, 2023;
originally announced June 2023.
-
The Brain Tumor Segmentation (BraTS) Challenge 2023: Glioma Segmentation in Sub-Saharan Africa Patient Population (BraTS-Africa)
Authors:
Maruf Adewole,
Jeffrey D. Rudie,
Anu Gbadamosi,
Oluyemisi Toyobo,
Confidence Raymond,
Dong Zhang,
Olubukola Omidiji,
Rachel Akinola,
Mohammad Abba Suwaid,
Adaobi Emegoakor,
Nancy Ojo,
Kenneth Aguh,
Chinasa Kalaiwo,
Gabriel Babatunde,
Afolabi Ogunleye,
Yewande Gbadamosi,
Kator Iorpagher,
Evan Calabrese,
Mariam Aboian,
Marius Linguraru,
Jake Albrecht,
Benedikt Wiestler,
Florian Kofler,
Anastasia Janas,
Dominic LaBella
, et al. (26 additional authors not shown)
Abstract:
Gliomas are the most common type of primary brain tumors. Although gliomas are relatively rare, they are among the deadliest types of cancer, with a survival rate of less than 2 years after diagnosis. Gliomas are challenging to diagnose, hard to treat and inherently resistant to conventional therapy. Years of extensive research to improve diagnosis and treatment of gliomas have decreased mortality…
▽ More
Gliomas are the most common type of primary brain tumors. Although gliomas are relatively rare, they are among the deadliest types of cancer, with a survival rate of less than 2 years after diagnosis. Gliomas are challenging to diagnose, hard to treat and inherently resistant to conventional therapy. Years of extensive research to improve diagnosis and treatment of gliomas have decreased mortality rates across the Global North, while chances of survival among individuals in low- and middle-income countries (LMICs) remain unchanged and are significantly worse in Sub-Saharan Africa (SSA) populations. Long-term survival with glioma is associated with the identification of appropriate pathological features on brain MRI and confirmation by histopathology. Since 2012, the Brain Tumor Segmentation (BraTS) Challenge have evaluated state-of-the-art machine learning methods to detect, characterize, and classify gliomas. However, it is unclear if the state-of-the-art methods can be widely implemented in SSA given the extensive use of lower-quality MRI technology, which produces poor image contrast and resolution and more importantly, the propensity for late presentation of disease at advanced stages as well as the unique characteristics of gliomas in SSA (i.e., suspected higher rates of gliomatosis cerebri). Thus, the BraTS-Africa Challenge provides a unique opportunity to include brain MRI glioma cases from SSA in global efforts through the BraTS Challenge to develop and evaluate computer-aided-diagnostic (CAD) methods for the detection and characterization of glioma in resource-limited settings, where the potential for CAD tools to transform healthcare are more likely.
△ Less
Submitted 30 May, 2023;
originally announced May 2023.
-
The Brain Tumor Segmentation (BraTS) Challenge 2023: Focus on Pediatrics (CBTN-CONNECT-DIPGR-ASNR-MICCAI BraTS-PEDs)
Authors:
Anahita Fathi Kazerooni,
Nastaran Khalili,
Xinyang Liu,
Debanjan Haldar,
Zhifan Jiang,
Syed Muhammed Anwar,
Jake Albrecht,
Maruf Adewole,
Udunna Anazodo,
Hannah Anderson,
Sina Bagheri,
Ujjwal Baid,
Timothy Bergquist,
Austin J. Borja,
Evan Calabrese,
Verena Chung,
Gian-Marco Conte,
Farouk Dako,
James Eddy,
Ivan Ezhov,
Ariana Familiar,
Keyvan Farahani,
Shuvanjan Haldar,
Juan Eugenio Iglesias,
Anastasia Janas
, et al. (48 additional authors not shown)
Abstract:
Pediatric tumors of the central nervous system are the most common cause of cancer-related death in children. The five-year survival rate for high-grade gliomas in children is less than 20\%. Due to their rarity, the diagnosis of these entities is often delayed, their treatment is mainly based on historic treatment concepts, and clinical trials require multi-institutional collaborations. The MICCA…
▽ More
Pediatric tumors of the central nervous system are the most common cause of cancer-related death in children. The five-year survival rate for high-grade gliomas in children is less than 20\%. Due to their rarity, the diagnosis of these entities is often delayed, their treatment is mainly based on historic treatment concepts, and clinical trials require multi-institutional collaborations. The MICCAI Brain Tumor Segmentation (BraTS) Challenge is a landmark community benchmark event with a successful history of 12 years of resource creation for the segmentation and analysis of adult glioma. Here we present the CBTN-CONNECT-DIPGR-ASNR-MICCAI BraTS-PEDs 2023 challenge, which represents the first BraTS challenge focused on pediatric brain tumors with data acquired across multiple international consortia dedicated to pediatric neuro-oncology and clinical trials. The BraTS-PEDs 2023 challenge focuses on benchmarking the development of volumentric segmentation algorithms for pediatric brain glioma through standardized quantitative performance evaluation metrics utilized across the BraTS 2023 cluster of challenges. Models gaining knowledge from the BraTS-PEDs multi-parametric structural MRI (mpMRI) training data will be evaluated on separate validation and unseen test mpMRI dataof high-grade pediatric glioma. The CBTN-CONNECT-DIPGR-ASNR-MICCAI BraTS-PEDs 2023 challenge brings together clinicians and AI/imaging scientists to lead to faster development of automated segmentation techniques that could benefit clinical trials, and ultimately the care of children with brain tumors.
△ Less
Submitted 23 May, 2024; v1 submitted 26 May, 2023;
originally announced May 2023.
-
The Brain Tumor Segmentation (BraTS) Challenge: Local Synthesis of Healthy Brain Tissue via Inpainting
Authors:
Florian Kofler,
Felix Meissen,
Felix Steinbauer,
Robert Graf,
Stefan K Ehrlich,
Annika Reinke,
Eva Oswald,
Diana Waldmannstetter,
Florian Hoelzl,
Izabela Horvath,
Oezguen Turgut,
Suprosanna Shit,
Christina Bukas,
Kaiyuan Yang,
Johannes C. Paetzold,
Ezequiel de da Rosa,
Isra Mekki,
Shankeeth Vinayahalingam,
Hasan Kassem,
Juexin Zhang,
Ke Chen,
Ying Weng,
Alicia Durrer,
Philippe C. Cattin,
Julia Wolleb
, et al. (81 additional authors not shown)
Abstract:
A myriad of algorithms for the automatic analysis of brain MR images is available to support clinicians in their decision-making. For brain tumor patients, the image acquisition time series typically starts with an already pathological scan. This poses problems, as many algorithms are designed to analyze healthy brains and provide no guarantee for images featuring lesions. Examples include, but ar…
▽ More
A myriad of algorithms for the automatic analysis of brain MR images is available to support clinicians in their decision-making. For brain tumor patients, the image acquisition time series typically starts with an already pathological scan. This poses problems, as many algorithms are designed to analyze healthy brains and provide no guarantee for images featuring lesions. Examples include, but are not limited to, algorithms for brain anatomy parcellation, tissue segmentation, and brain extraction. To solve this dilemma, we introduce the BraTS inpainting challenge. Here, the participants explore inpainting techniques to synthesize healthy brain scans from lesioned ones. The following manuscript contains the task formulation, dataset, and submission procedure. Later, it will be updated to summarize the findings of the challenge. The challenge is organized as part of the ASNR-BraTS MICCAI challenge.
△ Less
Submitted 22 September, 2024; v1 submitted 15 May, 2023;
originally announced May 2023.
-
The University of California San Francisco Brain Metastases Stereotactic Radiosurgery (UCSF-BMSR) MRI Dataset
Authors:
Jeffrey D. Rudie,
Rachit Saluja,
David A. Weiss,
Pierre Nedelec,
Evan Calabrese,
John B. Colby,
Benjamin Laguna,
John Mongan,
Steve Braunstein,
Christopher P. Hess,
Andreas M. Rauschecker,
Leo P. Sugrue,
Javier E. Villanueva-Meyer
Abstract:
The University of California San Francisco Brain Metastases Stereotactic Radiosurgery (UCSF-BMSR) dataset is a public, clinical, multimodal brain MRI dataset consisting of 560 brain MRIs from 412 patients with expert annotations of 5136 brain metastases. Data consists of registered and skull stripped T1 post-contrast, T1 pre-contrast, FLAIR and subtraction (T1 pre-contrast - T1 post-contrast) imag…
▽ More
The University of California San Francisco Brain Metastases Stereotactic Radiosurgery (UCSF-BMSR) dataset is a public, clinical, multimodal brain MRI dataset consisting of 560 brain MRIs from 412 patients with expert annotations of 5136 brain metastases. Data consists of registered and skull stripped T1 post-contrast, T1 pre-contrast, FLAIR and subtraction (T1 pre-contrast - T1 post-contrast) images and voxelwise segmentations of enhancing brain metastases in NifTI format. The dataset also includes patient demographics, surgical status and primary cancer types. The UCSF-BSMR has been made publicly available in the hopes that researchers will use these data to push the boundaries of AI applications for brain metastases. The dataset is freely available for non-commercial use at https://imagingdatasets.ucsf.edu/dataset/1
△ Less
Submitted 30 May, 2024; v1 submitted 14 April, 2023;
originally announced April 2023.
-
The University of California San Francisco Preoperative Diffuse Glioma MRI (UCSF-PDGM) Dataset
Authors:
Evan Calabrese,
Javier E. Villanueva-Meyer,
Jeffrey D. Rudie,
Andreas M. Rauschecker,
Ujjwal Baid,
Spyridon Bakas,
Soonmee Cha,
John T. Mongan,
Christopher P. Hess
Abstract:
Here we present the University of California San Francisco Preoperative Diffuse Glioma MRI (UCSF-PDGM) dataset. The UCSF-PDGM dataset includes 500 subjects with histopathologically-proven diffuse gliomas who were imaged with a standardized 3 Tesla preoperative brain tumor MRI protocol featuring predominantly 3D imaging, as well as advanced diffusion and perfusion imaging techniques. The dataset al…
▽ More
Here we present the University of California San Francisco Preoperative Diffuse Glioma MRI (UCSF-PDGM) dataset. The UCSF-PDGM dataset includes 500 subjects with histopathologically-proven diffuse gliomas who were imaged with a standardized 3 Tesla preoperative brain tumor MRI protocol featuring predominantly 3D imaging, as well as advanced diffusion and perfusion imaging techniques. The dataset also includes isocitrate dehydrogenase (IDH) mutation status for all cases and O6-methylguanine-DNA methyltransferase (MGMT) promotor methylation status for World Health Organization (WHO) grade III and IV gliomas. The UCSF-PDGM has been made publicly available in the hopes that researchers around the world will use these data to continue to push the boundaries of AI applications for diffuse gliomas.
△ Less
Submitted 15 March, 2022; v1 submitted 30 August, 2021;
originally announced September 2021.
-
The RSNA-ASNR-MICCAI BraTS 2021 Benchmark on Brain Tumor Segmentation and Radiogenomic Classification
Authors:
Ujjwal Baid,
Satyam Ghodasara,
Suyash Mohan,
Michel Bilello,
Evan Calabrese,
Errol Colak,
Keyvan Farahani,
Jayashree Kalpathy-Cramer,
Felipe C. Kitamura,
Sarthak Pati,
Luciano M. Prevedello,
Jeffrey D. Rudie,
Chiharu Sako,
Russell T. Shinohara,
Timothy Bergquist,
Rong Chai,
James Eddy,
Julia Elliott,
Walter Reade,
Thomas Schaffter,
Thomas Yu,
Jiaxin Zheng,
Ahmed W. Moawad,
Luiz Otavio Coelho,
Olivia McDonnell
, et al. (78 additional authors not shown)
Abstract:
The BraTS 2021 challenge celebrates its 10th anniversary and is jointly organized by the Radiological Society of North America (RSNA), the American Society of Neuroradiology (ASNR), and the Medical Image Computing and Computer Assisted Interventions (MICCAI) society. Since its inception, BraTS has been focusing on being a common benchmarking venue for brain glioma segmentation algorithms, with wel…
▽ More
The BraTS 2021 challenge celebrates its 10th anniversary and is jointly organized by the Radiological Society of North America (RSNA), the American Society of Neuroradiology (ASNR), and the Medical Image Computing and Computer Assisted Interventions (MICCAI) society. Since its inception, BraTS has been focusing on being a common benchmarking venue for brain glioma segmentation algorithms, with well-curated multi-institutional multi-parametric magnetic resonance imaging (mpMRI) data. Gliomas are the most common primary malignancies of the central nervous system, with varying degrees of aggressiveness and prognosis. The RSNA-ASNR-MICCAI BraTS 2021 challenge targets the evaluation of computational algorithms assessing the same tumor compartmentalization, as well as the underlying tumor's molecular characterization, in pre-operative baseline mpMRI data from 2,040 patients. Specifically, the two tasks that BraTS 2021 focuses on are: a) the segmentation of the histologically distinct brain tumor sub-regions, and b) the classification of the tumor's O[6]-methylguanine-DNA methyltransferase (MGMT) promoter methylation status. The performance evaluation of all participating algorithms in BraTS 2021 will be conducted through the Sage Bionetworks Synapse platform (Task 1) and Kaggle (Task 2), concluding in distributing to the top ranked participants monetary awards of $60,000 collectively.
△ Less
Submitted 12 September, 2021; v1 submitted 5 July, 2021;
originally announced July 2021.